Eph receptors and ephrins in cancer: Bidirectional signalling and beyond

Nature Reviews Cancer

Volumn 10, Issue 3, 2010, Pages 165-180

  Pasquale, Elena B ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANILINOPYRIMIDINE DERIVATIVE; BENZENESULFONAMIDE DERIVATIVE; CONTRAST MEDIUM; DASATINIB; EPHRIN; EPHRIN A1; EPHRIN A2; EPHRIN A4; EPHRIN A5; EPHRIN B2; EPHRIN B4; EPHRIN RECEPTOR; GAMMA SECRETASE; LDN 211904; METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1G9 H7; MONOCLONAL ANTIBODY AB20; NILOTINIB; OLIGONUCLEOTIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN ADAM19; PROTEIN TYROSINE KINASE; PSEUDOMONAS EXOTOXIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; XANTHINE DERIVATIVE; XL 647;

ANGIOGENESIS; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG TARGETING; EPIGENETICS; GENE MUTATION; GENE SILENCING; HUMAN; IN VIVO STUDY; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; RNA STABILITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; EPHRINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECEPTORS, EPH FAMILY; SIGNAL TRANSDUCTION;

EID: 77649114060     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2806     Document Type: Review

References (228)

1. Pasquale, E. B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38-52 (2008).
2. Hirai, H., Maru, Y., Hagiwara, K., Nishida, J. & Takaku, F. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238, 1717-1720 (1987).
3. Maru, Y., Hirai, H. & Takaku, F. Overexpression confers an oncogenic potential upon the eph gene. Oncogene 5, 445-447 (1990).
4. Bartley, T. D. et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 368, 558-560 (1994).
5. Pasquale, E. B. Eph receptor signalling casts a wide net on cell behaviour. Nature Rev. Mol. Cell Biol. 6, 462-475 (2005).
6. Arvanitis, D. & Davy, A. Eph/ephrin signaling: networks. Genes Dev. 22, 416-429 (2008).
7. Klein, R. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nature Neurosci. 12, 15-20 (2009).
8. Miao, H. & Wang, B. Eph/ephrin signaling in epithelial development and homeostasis. Int. J. Biochem. Cell Biol. 41, 762-770 (2009).
9. Alford, S. C., Bazowski, J., Lorimer, H., Elowe, S. & Howard, P. L. Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp. Cell Res. 313, 4170-4179 (2007).
10. Wykosky, J. et al. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 27, 7260-7273 (2008).
11. Gu, C. & Park, S. The EphA8 receptor regulates integrin activity through p110γ phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol. Cell. Biol. 21, 4579-4597 (2001).
12. Matsuoka, H., Obama, H., Kelly, M. L., Matsui, T. & Nakamoto, M. Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion and migration. J. Biol. Chem. 280, 29355-29363 (2005).
13. Miao, H. et al. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. J. Biol. Chem. 280, 923-932 (2005).
14. Georgakopoulos, A. et al. Metalloproteinase/ Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. EMBO J. 25, 1242-1252 (2006).
15. Hattori, M., Osterfield, M. & Flanagan, J. G. Regulated cleavage of a contact-mediated axon repellent. Science 289, 1360-1365 (2000).
16. Litterst, C. et al. Ligand binding and calcium influx induce distinct ectodomain/γ-secretase-processing pathways of EphB2 receptor. J. Biol. Chem. 282, 16155-16163 (2007).
17. Tanaka, M., Sasaki, K., Kamata, R. & Sakai, R. The C-terminus of ephrin-B1 regulates metalloproteinase secretion and invasion of cancer cells. J. Cell Sci. 120, 2179-2189 (2007).
18. Lin, K. T., Sloniowski, S., Ethell, D. W. & Ethell, I. M. Ephrin-B2-induced cleavage of EphB2 receptor is mediated by matrix metalloproteinases to trigger cell repulsion. J. Biol. Chem. 283, 28969-28979 (2008).
19. Orsulic, S. & Kemler, R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J. Cell Sci. 11 3, 1793-1802 (2000).
20. Zantek, N. D. et al. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 10, 629-638 (1999).
21. Yumoto, N. et al. Meltrin beta/ADAM19 interacting with EphA4 in developing neural cells participates in formation of the neuromuscular junction. PLoS ONE 3, e3322 (2008).
22. Kemp, H. A., Cooke, J. E. & Moens, C. B. EphA4 and EfnB2a maintain rhombomere coherence by independently regulating intercalation of progenitor cells in the zebrafish neural keel. Dev. Biol. 327, 313-326 (2009).
23. Batlle, E. et al. EphB receptor activity suppresses colorectal cancer progression. Nature 435, 1126-1130 (2005).
24. Inoue, E. et al. Synaptic activity prompts γ-secretase-mediated cleavage of EphA4 and dendritic spine formation. J. Cell Biol. 185, 551-564 (2009).
25. Wu, C. et al. ZHX2 Interacts with Ephrin-B and regulates neural progenitor maintenance in the developing cerebral cortex. J. Neurosci. 29, 7404-7412 (2009).
26. Surawska, H., Ma, P. C. & Salgia, R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 15, 419-433 (2004).
27. Ireton, R. C. & Chen, J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr. Cancer Drug Targets. 5, 149-157 (2005).
28. Landen, C. N., Kinch, M. S. & Sood, A. K. EphA2 as a target for ovarian cancer therapy. Expert Opin. Ther. Targets. 9, 1179-1187 (2005).
29. Noren, N. K. & Pasquale, E. B. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 67, 3994-3997 (2007).
30. Castano, J., Davalos, V., Schwartz, S. Jr & Arango, D. EPH receptors in cancer. Histol. Histopathol. 23, 1011-1023 (2008).
31. Wykosky, J. & Debinski, W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 6, 1795-1806 (2008).
32. McCarron, J. K., Stringer, B. W., Day, B. W. & Boyd, A. W. Ephrin expression and function in cancer. Future Oncol. 6, 165-176 (2010).
33. Zhuang, G. et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70, 299-308 (2010).
34. Huang, F. et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 67, 2226-2238 (2007). (Pubitemid 46424242)
35. Wang, X. D. et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol. 8, R255 (2007).
36. Kumar, S. R. et al. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br. J. Cancer 96, 1083-1091 (2007).
37. Kumar, S. R. et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 69, 3736-3745 (2009).
38. Hafner, C., Becker, B., Landthaler, M. & Vogt, T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod. Pathol. 19, 1369-1377 (2006).
39. Herath, N. I., Doecke, J., Spanevello, M. D., Leggett, B. A. & Boyd, A. W. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br. J. Cancer 100, 1095-1102 (2009).
40. Alazzouzi, H. et al. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res. 65, 10170-10173 (2005).
41. Davalos, V. et al. EPHB4 and survival of colorectal cancer patients. Cancer Res. 66, 8943-8948 (2006).
42. Chiu, S. T. et al. Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis 30, 1475-1486 (2009).
43. Li, J. J., Liu, D. P., Liu, G. T. & Xie, D. EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene 28, 1759-1768 (2009).
44. Muller-Tidow, C. et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res. 65, 1778-1782 (2005).
45. Fu, T. et al. c-Rel is a transcriptional repressor of EPHB2 in colorectal cancer. J. Pathol. 219, 103-113 (2009).
46. Macrae, M. et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8, 111-118 (2005).
47. Noren, N. K., Foos, G., Hauser, C. A. & Pasquale, E. B. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nature Cell Biol. 8, 815-825 (2006).
48. Sulman, E. P. et al. ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40, 371-374 (1997).
49. Huusko, P. et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genet. 36, 979-983 (2004).
50. Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W. & Kim, J. M. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 9, 237 (2009).
51. Winter, J. et al. Comparative 3'UTR analysis allows identification of regulatory clusters that drive Eph/ ephrin expression in cancer cell lines. PLoS ONE 3, e2780 (2008).
52. Pandey, A., Shao, H., Marks, R. M., Polverini, P. J. & Dixit, V. M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science 268, 567-569 (1995).
53. Cheng, N. et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 1, 2-11 (2002).
54. Yamashita, T. et al. Hypoxia-inducible transcription factor-2α in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J. Biol. Chem. 283, 18926-18936 (2008).
55. Heroult, M., Schaffner, F. & Augustin, H. G. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp. Cell Res. 312, 642-650 (2006).
56. Pasquale, E. B. in Modern concepts in angiogenesis (eds. Simons, M. & Rubanyi, G.) 27-66 (Imperial College Press, London, 2007).
57. Kuijper, S., Turner, C. J. & Adams, R. H. Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc. Med. 17, 145-151 (2007).
58. Korff, T., Braun, J., Pfaff, D., Augustin, H. G. & Hecker, M. Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment. Blood 11 2, 73-81 (2008).
59. Obi, S. et al. Fluid shear stress induces arterial differentiation of endothelial progenitor cells. J. Appl. Physiol. 106, 203-211 (2009).
60. Foo, S. S. et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 124, 161-173 (2006).
61. Hafner, C. et al. Differential gene expression of Eph receptors and Ephrins in benign human tissues and cancers. Clin. Chem. 50, 490-499 (2004).
62. Fasanaro, P. et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J. Biol. Chem. 283, 15878-15883 (2008).
63. Davies, H. et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65, 7591-7595 (2005).
64. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
65. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
66. Ruhe, J. E. et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 67, 11368-11376 (2007).
67. Prickett, T. D. et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nature Genet. 41, 1127-1132 (2009).
68. Davalos, V. et al. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene 26, 308-311 (2007).
69. Zogopoulos, G. et al. Germline EPHB2 receptor variants in familial colorectal cancer. PLoS ONE 3, e2885 (2008).
70. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
71. Zelinski, D. P., Zantek, N. D., Stewart, J. C., Irizarry, A. R. & Kinch, M. S. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 61, 2301-2306 (2001).
72. Miao, H. et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20 (2009).
73. Dopeso, H. et al. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res. 69, 7430-7438 (2009).
74. Noblitt, L. W. et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. 11, 757-766 (2004).
75. Hess, A. R. et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol. Ther. 5, 228-233 (2006).
76. Wimmer-Kleikamp, S. H. et al. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 11 2, 721-732 (2008).
77. Kikawa, K. D., Vidale, D. R., Van Etten, R. L. & Kinch, M. S. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J. Biol. Chem. 277, 39274-39279 (2002).
78. Shintani, T. et al. Eph receptors are negatively controlled by protein tyrosine phosphatase receptor type O. Nature Neurosci. 9, 761-769 (2006).
79. Poliakov, A., Cotrina, M. L., Pasini, A. & Wilkinson, D. G. Regulation of EphB2 activation and cell repulsion by feedback control of the MAPK pathway. J. Cell Biol. 183, 933-947 (2008).
80. Brisbin, S. et al. A role for C. elegans Eph RTK signaling in PTEN regulation. Dev. Cell 17, 459-469 (2009).
81. Smith, F. M. et al. Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J. Biol. Chem. 279, 9522-9531 (2004).
82. Zisch, A. H. & Pasquale, E. B. The Eph family: a multitude of receptors that mediate cell recognition signals. Cell Tissue Res. 290, 217-226 (1997).
83. Jin, P. et al. Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Res. Ther. 10, R73 (2008).
84. Tsuda, H. et al. The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell 133, 963-977 (2008).
85. Guo, H. et al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res. 66, 7050-7058 (2006).
86. Cortina, C. et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nature Genet. 39, 1376-1383 (2007).
87. Lee, H. S., Nishanian, T. G., Mood, K., Bong, Y. S. & Daar, I. O. EphrinB1 controls cell-cell junctions through the Par polarity complex. Nature Cell Biol. 10, 979-986 (2008).
88. Jorgensen, C. et al. Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326, 1502-1509 (2009).
89. Almog, N. et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 69, 836-844 (2009).
90. Leroy, C. et al. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res. 69, 2279-2286 (2009).
91. Genander, M. et al. Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell 139, 679-692 (2009).
92. Fang, W. B., Brantley-Sieders, D. M., Parker, M. A., Reith, A. D. & Chen, J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24, 7859-7868 (2005).
93. Yang, N. Y., Pasquale, E. B., Owen, L. B. & Ethell, I. M. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J. Biol. Chem. 281, 32574-32586 (2006).
94. Parri, M., Taddei, M. L., Bianchini, F., Calorini, L. & Chiarugi, P. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res. 69, 2072-2081 (2009).
95. Wang, J. Y. et al. Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol. Ther. 7, 758-766 (2008).
96. Nakada, M., Niska, J. A., Tran, N. L., McDonough, W. S. & Berens, M. E. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am. J. Pathol. 167, 565-576 (2005).
97. Noren, N. K., Yang, N. Y., Silldorff, M., Mutyala, R. & Pasquale, E. B. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. Biochem. J. 422, 433-442 (2009).
98. Yokote, H. et al. Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc. Natl Acad. Sci. USA 102, 18866-18871 (2005).
99. Fukai, J. et al. EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol. Cancer Ther. 7, 2768-2778 (2008).
100. Carles-Kinch, K., Kilpatrick, K. E., Stewart, J. C. & Kinch, M. S. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 62, 2840-2847 (2002).
101. Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W. & Whang, E. E. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23, 1448-1456 (2004).
102. Landen, C. N. Jr et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
103. Fang, W. B. et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J. Cell Sci. 121, 358-368 (2008).
104. Larsen, A. B. et al. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol. Cancer Res. 5, 283-293 (2007).
105. Brantley-Sieders, D. M. et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 11 8, 64-78 (2008).
106. Vaught, D., Chen, J. & Brantley-Sieders, D. M. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol. Biol. Cell 20, 2572-2581 (2009).
107. Huang, X., Wu, D., Jin, H., Stupack, D. & Wang, J. Y. Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling. J. Cell Biol. 183, 711-723 (2008).
108. Furne, C. et al. EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis. Biochim. Biophys. Acta 1793, 231-238 (2009).
109. Iida, H. et al. Ephrin-A1 expression contributes to the malignant characteristics of α-fetoprotein producing hepatocellular carcinoma. Gut 54, 843-851 (2005).
110. Campbell, T. N., Attwell, S., Arcellana-Panlilio, M. & Robbins, S. M. Ephrin A5 expression promotes invasion and transformation of murine fibroblasts. Biochem. Biophys. Res. Commun. 350, 623-628 (2006).
111. Tanaka, M., Kamata, R. & Sakai, R. Phosphorylation of ephrin-B1 via the interaction with claudin following cell-cell contact formation. EMBO J. 24, 3700-3711 (2005).
112. Nakada, M., Drake, K. L., Nakada, S., Niska, J. A. & Berens, M. E. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res. 66, 8492-8500 (2006).
113. Jiang, G. et al. In human leukemia cells ephrin-B-induced invasive activity is supported by Lck and is associated with reassembling of lipid raft signaling complexes. Mol. Cancer Res. 6, 291-305 (2008).
114. Xu, N. J. & Henkemeyer, M. Ephrin-B3 reverse signaling through Grb4 and cytoskeletal regulators mediates axon pruning. Nature Neurosci. 12, 268-276 (2009).
115. Meyer, S. et al. Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int. J. Oncol. 27, 1197-1206 (2005).
116. Nakada, M. et al. The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion. Int. J. Cancer 126, 1155-1165 (2010).
117. Tanaka, M., Kamata, R., Takigahira, M., Yanagihara, K. & Sakai, R. Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma. Am. J. Pathol. 171, 68-78 (2007).
118. Bong, Y. S. et al. ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc. Natl Acad. Sci. USA 104, 17305-17310 (2007).
119. Shekhar, M. P., Werdell, J., Santner, S. J., Pauley, R. J. & Tait, L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 61, 1320-1326 (2001).
120. Okazaki, T. et al. Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice. Am. J. Pathol. 174, 2388-2399 (2009).
121. Larson, J., Schomberg, S., Schroeder, W. & Carpenter, T. C. Endothelial EphA receptor stimulation increases lung vascular permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L431-439 (2008).
122. Ogawa, K. et al. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19, 6043-6052 (2000).
123. Brantley-Sieders, D. M., Fang, W. B., Hwang, Y., Hicks, D. & Chen, J. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis- dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res. 66, 10315-10324 (2006).
124. Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
125. Herbert, S. P. et al. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 326, 294-298 (2009).
126. Erber, R. et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 25, 628-641 (2006).
127. Noren, N. K., Lu, M., Freeman, A. L., Koolpe, M. & Pasquale, E. B. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc. Natl Acad. Sci. USA 101, 5583-5588 (2004).
128. Salvucci, O. et al. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 11 4, 1707-1716 (2009).
129. Huang, J. et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. 2, 36-42 (2004).
130. Foubert, P. et al. PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells. J. Clin. Invest. 11 7, 1527-1537 (2007).
131. Pfaff, D. et al. Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes. J. Cell Sci. 121, 3842-3850 (2008).
132. Miyazaki, Y. et al. Design and effective synthesis of novel templates, 3, 7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. Bioorg. Med. Chem. Lett. 17, 250-254 (2007).
133. Bardelle, C. et al. Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3, 5-bis substituted anilinopyrimidines. Bioorg. Med. Chem. Lett. 18, 5717-5721 (2008).
134. Choi, Y. et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 19, 4467-4470 (2009).
135. Lafleur, K., Huang, D., Zhou, T., Caflisch, A. & Nevado, C. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J. Med. Chem. 52, 6433-6446 (2009).
136. Qiao, L. et al. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 19, 6122-6126 (2009).
137. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127-132 (2008).
138. Chang, Q., Jorgensen, C., Pawson, T. & Hedley, D. W. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br. J. Cancer 99, 1074-1082 (2008).
139. Shahzad, M. M. et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol. Ther. 8, 1027-1034 (2009).
140. Annamalai, B., Liu, X., Gopal, U. & Isaacs, J. S. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol. Cancer Res. 7, 1021-1032 (2009).
141. + T cells. Cancer Res. 69, 6995-7003 (2009).
142. Scehnet, J. S. et al. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 11 3, 254-263 (2009).
143. Mao, W. et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 64, 781-788 (2004).
144. Xu, Z., Jin, H. & Qian, Q. Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases. Expert Opin. Ther. Pat 19, 1035-1037 (2009).
145. Koolpe, M., Burgess, R., Dail, M. & Pasquale, E. B. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J. Biol. Chem. 280, 17301-17311 (2005).
146. Koolpe, M., Dail, M. & Pasquale, E. B. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J. Biol. Chem. 277, 46974-46979 (2002).
147. Murai, K. K. et al. Targeting the EphA4 receptor in the nervous system with biologically active peptides. Mol. Cell Neurosci. 24, 1000-1011 (2003).
148. Chrencik, J. E. et al. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 14, 321-330 (2006).
149. Chrencik, J. E. et al. Three-dimensional Structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J. Biol. Chem. 282, 36505-36513 (2007).
150. Noberini, R. et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J. Biol. Chem. 283, 29461-29472 (2008).
151. Qin, H., Shi, J., Noberini, R., Pasquale, E. B. & Song, J. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor. J. Biol. Chem. 283, 29473-29484 (2008).
152. Coffman, K. T. et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 63, 7907-7912 (2003).
153. Landen, C. N. Jr et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl Cancer Inst. 98, 1558-1570 (2006).
154. + tumors in vitro and in vivo after treatment with ligand agonists. J. Immunol. 181, 7721-7727 (2008).
155. Bruckheimer, E. M. et al. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 11, 509-517 (2009).
156. Kiewlich, D. et al. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 8, 18-30 (2006).
157. Jackson, D. et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 68, 9367-9374 (2008).
158. Lee, J. W. et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 101, 1193-1205 (2009).
159. Gobin, A. M., Moon, J. J. & West, J. L. EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells. Int. J. Nanomedicine 3, 351-358 (2008).
160. Cai, W. et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur. J. Nucl. Med. Mol. Imaging 34, 2024-2036 (2007).
161. Vearing, C. et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res. 65, 6745-6754 (2005).
162. Hammond, S. A. et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res. 67, 3927-3935 (2007).
163. Chiari, R. et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 60, 4855-4863 (2000).
164. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 63, 4481-4489 (2003).
165. Alves, P. M. et al. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res. 63, 8476-8480 (2003).
166. + glioma patients. Cancer Sci. 99, 1656-1662 (2008).
167. Hatano, M. et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7, 717-722 (2005).
168. Yamaguchi, S. et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 110, 1469-1477 (2007).
169. Scott, J. D. & Pawson, T. Cell signaling in space and time: where proteins come together and when they're apart. Science 326, 1220-1224 (2009).
170. Miura, K., Nam, J. M., Kojima, C., Mochizuki, N. & Sabe, H. EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts. Mol. Biol. Cell 20, 1949-1959 (2009).
171. Miao, H. et al. EphA kinase activation regulates HGF-induced epithelial branching morphogenesis. J. Cell Biol. 162, 1281-1292 (2003).
172. Barrios, A. et al. Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition of the paraxial mesoderm during somite morphogenesis. Curr. Biol. 13, 1571-1582 (2003).
173. Cooper, M. A. et al. Loss of ephrin-A5 function disrupts lens fiber cell packing and leads to cataract. Proc. Natl Acad. Sci. USA 105, 16620-16625 (2008).
174. Jun, G. et al. EPHA2 is associated with age-related cortical cataract in mice and humans. PLoS Genet. 5, e1000584 (2009).
175. Noren, N. K. & Pasquale, E. B. Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal 16, 655-666 (2004).
176. Kalo, M. S. & Pasquale, E. B. Multiple in vivo tyrosine phosphorylation sites in EphB receptors. Biochemistry 38, 14396-14408 (1999).
177. Lim, Y. S. et al. p75(NTR) mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron 59, 746-758 (2008).
178. Miao, H. et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nature Cell Biol. 3, 527-530 (2001).
179. Menges, C. W. & McCance, D. J. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 27, 2934-2940 (2008).
180. Dail, M., Richter, M., Godement, P. & Pasquale, E. B. Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion. J. Cell Sci. 1 1 9, 1244-1254 (2006).
181. Nie, D. et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nature Neurosci. 13, 163-172 (2010).
182. Zhuang, G., Hunter, S., Hwang, Y. & Chen, J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J. Biol. Chem. 282, 2683-2694 (2007).
183. Takeuchi, S., Yamaki, N., Iwasato, T., Negishi, M. & Katoh, H. β2-chimaerin binds to EphA receptors and regulates cell migration. FEBS Lett. 583, 1237-1242 (2009).
184. Yamazaki, T. et al. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J. Cell Sci. 122, 243-255 (2009).
185. Lai, K. O. et al. Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholinesterase expression. J. Biol. Chem. 279, 13383-13392 (2004).
186. Hunter, S. G. et al. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol. Cell. Biol. 26, 4830-4842 (2006).
187. Frohling, S. & Dohner, H. Chromosomal abnormalities in cancer. N. Engl. J. Med. 359, 722-734 (2008).
188. Oba, S. M. et al. Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer. Cancer Letters 164, 97-104 (2001).
189. Laiho, P. et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 26, 312-320 (2007).
190. Ikegaki, N. et al. Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyrosine kinase gene of the EPH family. Hum. Mol. Genet. 4, 2033-2045 (1995).
191. Narayan, G. et al. Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 22, 3489-3499 (2003).
192. Kasahara, K. et al. Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet. Cytogenet. 137, 59-63 (2002).
193. Sinha, U. K. et al. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 132, 1053-1059 (2006).
194. Xia, G. et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 65, 4623-4632 (2005). (Pubitemid 40740798)
195. Yang, T. L. et al. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity. Genes Chromosom. Cancer 41, 250-256 (2004).
196. Dottori, M., Down, M., Huttmann, A., Fitzpatrick, D. R. & Boyd, A. W. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94, 2477-2486 (1999).
197. Guan, M., Xu, C., Zhang, F. & Ye, C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int. J. Cancer 124, 88-94 (2009).
198. Wang, J. et al. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum. Pathol. 38, 1649-1656 (2007).
199. Wang, J. et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24, 5637-5647 (2005).
200. Dawson, D. W. et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26, 4243-4252 (2007).
201. Nosho, K. et al. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 28, 1364-1370 (2007).
202. Fox, B. P. & Kandpal, R. P. Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. Biochem. Biophys. Res. Commun. 340, 268-276 (2006).
203. Pulkkinen, K., Malm, T., Turunen, M., Koistinaho, J. & Yla-Herttuala, S. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett. 582, 2397-2401 (2008).
204. Dohn, M., Jiang, J. Y. & Chen, X. B. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20, 6503-6515 (2001).
205. Jin, Y. J. et al. A novel mechanism for p53 to regulate its target gene ECK in signaling apoptosis. Mol. Cancer Res. 4, 769-778 (2006).
206. Yu, J. et al. Identification and classification of p53-regulated genes. Proc. Natl Acad. Sci. USA 96, 14517-14522 (1999).
207. van Doorn, R. et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res. 64, 5578-5586 (2004).
208. Ting, M. C. et al. EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis. Development 136, 855-864 (2009).
209. Batlle, E. et al. β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/EphrinB. Cell 111, 251-263 (2002).
210. Nikolova, Z., Djonov, V., Zuercher, G., Andres, A. C. & Ziemiecki, A. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J. Cell Sci. 111, 2741-2751 (1998).
211. Bardelle, C. et al. Inhibitors of the tyrosine kinase EphB4. Part 1:s-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg. Med. Chem. Lett. 18, 2776-2780 (2008).
212. Gendreau, S. B. et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin. Cancer Res. 13, 3713-3723 (2007).
213. Kolb, P., Kipouros, C. B., Huang, D. & Caflisch, A. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors. Proteins 73, 11-18 (2008).
214. Caligiuri, M. et al. MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells. Chem. Biol. 13, 711-722 (2006).
215. Melnick, J. S. et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl Acad. Sci. USA 103, 3153-3158 (2006).
216. Kumar, S. R. et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am. J. Pathol. 169, 279-293 (2006).
217. Xia, G. et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25, 769-780 (2006).
218. Dobrzanski, P. et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 64, 910-919 (2004).
219. Brantley, D. M. et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21, 7011-7026 (2002).
220. Cheng, N. et al. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 5, 445-456 (2003).
221. Martiny-Baron, G. et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 6, 248-257 (2004).
222. Kertesz, N. et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 107, 2330-2338 (2006).
223. Fabes, J., Anderson, P., Brennan, C. & Bolsover, S. Regeneration-enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord. Eur. J. Neurosci. 26, 2496-2505 (2007).
224. Salvucci, O. et al. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 11 4, 1707-1716 (2009).
225. van Geer, M. A. et al. Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J. Gastroenterol. 15, 2754-2762 (2009).
226. Wykosky, J., Gibo, D. M. & Debinski, W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol. Cancer Ther. 6, 3208-3218 (2007).
227. Scarberry, K. E., Dickerson, E. B., McDonald, J. F. & Zhang, Z. J. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J. Am. Chem. Soc. 130, 10258-10262 (2008).
228. Scarberry, K. E., Dickerson, E. B., Zhang, Z. J., Benigno, B. B. & McDonald, J. F. Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine 5 Dec 2009 (doi:10.1016/j.nano. 2009.11.003).